WITHDRAWAL OF RESOLUTIONS FROM THE ANNUAL GENERAL MEETING

Melbourne, Australia – 21 November 2024: Percheron Therapeutics Limited (ASX:PER or "**the Company**") wishes to advise that it has withdrawn the following resolutions from the Company's Annual General Meeting (**AGM**) to be held at 10:00am today:

Resolution 6 – Approval of 10% Placement Capacity
Resolutions 7 – Amendments to Constitution

The withdrawal of Resolution 6 and 7 does not affect the validity of proxy votes already submitted in respect of the remaining resolutions. All other items of business included in the Notice of Meeting and the Addendum to the Notice of Meeting provided will be put to shareholders at the AGM.

"The affected resolutions are largely routine procedural matters," commented Dr Charmaine Gittleson, Chair of the Board at Percheron. "However, we are aware that there have been certain misunderstandings and concerns among shareholders in respect of these resolutions and so we have elected to withdraw them from today's meeting. We will take time to listen carefully to the concerns that have been expressed and will look to reintroduce these resolutions as appropriate at a future meeting, at which time the intent and effect of the resolutions will be more clearly communicated. While the Board remains of the view that carrying these resolutions would have been advantageous to the company, we expect the near-term impact of their withdrawal to be minimal."

About Percheron Therapeutics Limited

Percheron Therapeutics Limited [ASX: PER | US OTC: ATHJF] is a publicly listed biotechnology company focused on the development and commercialisation of novel therapies for rare diseases. The company's lead program is avicursen (ATL1102), an antisense oligonucleotide targeting the CD49d receptor. Avicursen is currently the subject of an ongoing international phase IIb clinical trial for the treatment of non-ambulant patients with Duchenne Muscular Dystrophy (DMD), for which data is expected in December CY2024. The company previously reported promising results from an exploratory phase IIa study of in the same population and has been awarded orphan drug designation (ODD) and rare pediatric disease designation (RPDD) by the US FDA.

For more information, please contact info@PercheronTx.com.

This announcement has been authorized for release to the Australian Securities Exchange by the Company Secretary.
